Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer

Human Pathology

Volumn 28, Issue 10, 1997, Pages 1180-1188

  Lynch, Beverly J ^a   Guinee Jr , Donald G ^a   Holden, Joseph A ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Breast cancer; Cell proliferation; DNA topoisomerase II alpha; MIBI

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER INVASION; CELL CYCLE S PHASE; CELL PROLIFERATION; DRUG SENSITIVITY; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS INDEX; PROGNOSIS; TARGET CELL; TISSUE SECTION;

EID: 0030748978     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(97)90256-2     Document Type: Article

References (52)

1. Harris JR, Lippman ME, Veronesi U, et al: Breast cancer. N Engl J Med 327:319-328, 1992
2. Fisher B, Redmond C, Dimitrov NV, et al: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320:474-478, 1989
3. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
4. Mansour EG, Gray R, Shatila AH, et al: Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. N Engl J Med 320:485-490, 1989
5. Goldhirsch A, The Ludwig Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320:491-496, 1989
6. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
7. Huss HB, Thor AD, Berry D, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
8. Allred DC, Clark GM, Tandon AK, et al: Her2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
9. Meyer JS, Friedman E, McCrate M, et al: Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51:1879-1886, 1983
10. Clark GM, Dressier LG, Owens M, et al: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627-633, 1989
11. Clark GM, Mathieu M, Owens MA, et al: Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 10:428-432, 1992
12. Capranico G, Zunino F, Kohn KW, et al: Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: Relationship with DNA binding affinity and cytotoxicity. Biochemistry 29:562-569, 1990
13. Chung DU, Drake FH, Tan KB, et al: Characterization and immunological identification of cDNA clones encoding two human topoisomerase isozymes. Proc Natl Acad Sci USA 86:9431-9435, 1989
14. Drake FH, Hofmann GA, Bartus HF, et al: Biochemical and pharmacological properties of p 170 and p 180 forms of topoisomerase II. Biochemistry 28:8154-8160, 1989
15. Mirski SEL, Evans CD, Almquis KC, et al: Altered topoisomerase II-alpha in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 53:4866-4873, 1993
16. Campain JA, Gottesman MM, Pastan I: A novel mutant topoisomerase II-alpha present in a VP-16-resistant human melanoma cell lines has a deletion of alanine 429. Biochemistry 33:11327-11332, 1994
17. r 160,000 topoisomerase II-alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res 55:2129-2134, 1995
18. Hsiung Y, Jannatipour M, Rose A, et al: Functional expression of human topoisomerase II-alpha in yeast: Mutations at amino acids 450 or 803 of topoisomerase II-alpha result in enzymes that can confer resistance to anti-topoisomerase II agents. Cancer Res 56:91-99, 1996
19. Coutts J, Plumb JA, Brown R, et al: Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br J Cancer 68:793-800, 1993
20. Smith K, Houlbrook S, Greenall M, et al: Topoisomerase II-alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: Relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 8:933-938, 1993
21. Woessner RD, Mattern MR, Mirabelli CK, et al: Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2:209-214, 1991
22. Heck MMS, Earnshaw WC: Topoisomerase II: A specific marker for cell proliferation. J Cell Biol 103:2569-2581, 1986
23. Capranico G, Tinelli S, Austin CA, et al: Differential patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta 132:43-48, 1992
24. JuenkeJM, Holden JA: The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues. Biochim Biophys Acta 1216:191-196, 1993
25. Holden JA, Perkins SL, Snow GW, et al: Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Pathol 104:54-59, 1995
26. Efferth T, Mattern J, Volm M: Immunohistochemical detection of P glycoprotein, glutathione S transferase and DNA topoisomerase II in human tumors. Oncology 49:368-375, 1992
27. Hellemans P, van Dam PA, Geyskens M, et al: Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast. J Clin Pathol 48:147-150, 1995
28. Kaufmann SH, Mclaughlin SJ, Kastan MB, et al: Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 51:3534-3543, 1991
29. Holden JA, Rolfson DH, Wittwer CT: The distribution of immunoreactive topoisomerase II protein in human tissues and neoplasms. Oncol Res 4:157-166, 1992
30. Harker WG, Slade DL, Drake FH, et al: Mitoxantrone resistance in HL-60 leukemia cells: Reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase IIβ isoform. Biochemistry 30:9952-9961, 1991
31. Khelifa T, Casabianca-Pignede M, Rene B, et al: Expression of topoisomerases II alpha and beta in chinese hamster lung cells resistant to topoisomerase II inhibitors. Mol Pharmacol 46:323-328, 1994
32. Giaccone G, van Ark-Otte J, Scagliotti G, et al: Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim Biophys Acta 1264:337-346, 1995
33. Austin CA, Marsh KL, Wasserman RA, et al: Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIβ. J Biol Chem 270:15739-15746, 1995
34. Brown GA, McPhersonJP, Lie G, et al: Relationship of DNA topoisomerase II-alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res 55:78-82, 1995
35. D'Andrea MR, Farger PA, Foglesong PD: Immunohistochemical detection of DNA topoisomerases II alpha and II beta compared with detection of Ki-67, a marker of cellular proliferation, in human tumors. Appl Immunohist 2:177-185, 1994
36. Davies SM, Robson CN, Davies SL, et al: Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 263:17724-17729, 1988
37. Potmesil M, Hsaing Y, Liu LF, et al: Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 48:3537-3543, 1988
38. Nitiss JL, Ya-Xia L, Harbury P, et al: Amsacrine and etoposide hypersensitivity of yeast cell cells overexpressing DNA topoisomerase II. Cancer Res 52:4467-4472, 1992
39. Holden JA, Rolfson DH, Wittwer CT: Human DNA topoisomerase II: Evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry 29:2127-2134, 1990
40. Dalton LW, Page DL, Dupont WD: Histologic grading of breast carcinoma. Cancer 73:2765-2770, 1994
41. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72:248-254, 1976
42. Miller KG, Liu LF, Englund PT: A homogeneous type II DNA topoisomerase from Hela cell nuclei. J Biol Chem 256:9334-9339, 1981
43. Henson DE, Ries L, Freedman LS, et al: Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer: The basis for a prognostic index. Cancer 68:2142-2149, 1981
44. Duchrow M, Gerdes J, Schluter C: The proliferation-associated Ki-67 protein: Definition in molecular terms. Cell Prolif 27:235-242, 1994
45. Linden MD, El-Naggar AK, Nathanson SD, et al: Lack of correlation between flow cytometric and immunohistologic proliferation measurements of tumors. Mod Pathol 9:682-689, 1996
46. Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984
47. Berger JM, Gamblin SJ, Harrison SC, et al: Structure and mechanism of DNA topoisomerase II. Nature 379:225-232, 1996
48. Sinha BK: Topoisomerase inhibitors: A review of their therapeutic potential in cancer. Drugs 49:11-19, 1995
49. Houlbrook S, Addison CM, Davies SL, et al: Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 72:1453-1461, 1995
50. Sampson SA, Kreipe H, Gillett CE, et al: KiS1, a novel monoclonal antibody that recognizes proliferating cells: Evaluation of its relationship to prognosis in mammary carcinoma. J Pathol 168:179-185, 1992
51. Boege F, Andersen A, Jensen S, et al: Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II-alpha. Am J Pathol 146:1302-1308, 1995
52. Guinee DG, Holden JA, Benfield JR, et al: Comparison of DNA topoisomerase II-alpha expression in small cell and nonsmall cell carcinoma of the lung: In search of a mechanism of chemotherapeutic response. Cancer 78:729-735, 1996